275 related articles for article (PubMed ID: 19762071)
21. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
22. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
23. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
Pasternak B; Svanström H; Melbye M; Hviid A
JAMA Intern Med; 2014 Oct; 174(10):1597-604. PubMed ID: 25173681
[TBL] [Abstract][Full Text] [Related]
24. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Packer M
J Card Fail; 2003 Dec; 9(6):429-43. PubMed ID: 14966782
[TBL] [Abstract][Full Text] [Related]
25. Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
Boman K; Boman JH; Andersson J; Olofsson M; Dahlöf B
Clin Appl Thromb Hemost; 2010 Apr; 16(2):146-52. PubMed ID: 19825910
[TBL] [Abstract][Full Text] [Related]
26. The COMET trial.
Bristow MR; Adams KF; Bauman JL; Feldman AM; Giles TD; Goldstein S; Mann DL; Talbert RL
Congest Heart Fail; 2005; 11(1):39-47. PubMed ID: 15722669
[No Abstract] [Full Text] [Related]
27. [A fairer comparison between carvedilol and metoprolol is still to be done].
Johnsson G; Aberg J
Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
[No Abstract] [Full Text] [Related]
28. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
[TBL] [Abstract][Full Text] [Related]
29. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Cleland JG
Curr Heart Fail Rep; 2004 Jul; 1(2):82-8. PubMed ID: 16036030
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
32. Critical differences among beta-adrenoreceptor antagonists in myocardial failure: debating the MERIT of COMET.
McBride BF; White CM
J Clin Pharmacol; 2005 Jan; 45(1):6-24. PubMed ID: 15601801
[TBL] [Abstract][Full Text] [Related]
33. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.
Al-Hesayen A; Azevedo ER; Floras JS; Hollingshead S; Lopaschuk GD; Parker JD
Eur J Heart Fail; 2005 Jun; 7(4):618-23. PubMed ID: 15921803
[TBL] [Abstract][Full Text] [Related]
34. Carvedilol versus metoprolol in the acute phase of myocardial infarction:
Bonnemeier H; Ortak J; Tölg R; Witt M; Schmidt J; Wiegand UK; Bode F; Schunkert H; Richardt G
Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S222-6. PubMed ID: 15683501
[TBL] [Abstract][Full Text] [Related]
35. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.
Poole-Wilson PA; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Metra M; J Remme W; Swedberg K; Torp-Pedersen C
Eur J Heart Fail; 2002 Jun; 4(3):321-9. PubMed ID: 12034158
[TBL] [Abstract][Full Text] [Related]
36. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
37. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
Metra M; Torp-Pedersen C; Swedberg K; Cleland JG; Di Lenarda A; Komajda M; Remme WJ; Lutiger B; Scherhag A; Lukas MA; Charlesworth A; Poole-Wilson PA
Eur Heart J; 2005 Nov; 26(21):2259-68. PubMed ID: 16040619
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
39. Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Boman KO; Jansson JH; Nyhlén KA; Nilsson TK
Thromb Haemost; 2002 Feb; 87(2):311-6. PubMed ID: 11859853
[TBL] [Abstract][Full Text] [Related]
40. Carvedilol and metoprolol European trial: do the results merit challenge?
Smith KM
Am J Health Syst Pharm; 2004 Jun; 61(12):1289-93. PubMed ID: 15259762
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
